Hi Werble,A few days ago on the 4C thread, I posted the Poster...

Hi Werble,

A few days ago on the 4C thread, I posted the Poster Presentation of the trial design for this 2A FSGS trial. If you look at the figure in that of 2A allcomer trial with proteinuric kidney disease, you can see the results graphed there. Orange is DKD, dark blue IgA Nephropathy & light blue is “other proteinuric kidney disease diagnosis”. All these diseases cause scarring (sclerosis) of the kidneys as does FSGS. We don’t know the diagnoses of the “other” group.

This has the potential to be a game changer for the treatment of FSGS on good results.

A little bit about FSGS for anyone interested:

https://www.luriechildrens.org/en/specialties-conditions/fsgs/

Good luck everyone!

Just while we are all waiting, an interesting article on Adaptive clinical trials (REMAP-CAP included) for COVID-19 & collaborations that are happening. The data sharing is interesting over various platforms, a real time data lag of only 7 days, compared to traditional clinical trial designs. This will allow timely identification of treatments that are efficacious for COVID-19.

We should hear some news on this trial soon, with priority review for COVID trials, it’s been ~2 months since this was announced.

https://www.statnews.com/2020/07/23/using-a-global-network-of-adaptive-clinical-trials-to-fight-covid-19/

International COVID-19 Data Alliance and Workbench:

https://www.hdruk.ac.uk/covid-19/international-covid-19-data-alliance/

You can access the webinar & slides for Investigators here, for more information.

GLTAH